The Derivative Difluoroboranyl-Fluoroquinolone “7a” Generates Effective Inhibition Against the <i>S. aureus</i> Strain in a Murine Model of Acute Pneumonia

During the last decades, most bacterial strains have become increasingly resistant to antibiotics. This led the WHO to declare a global emergency in 2017 and urge the development of new active compounds. Some families of antibiotics still show high antibacterial efficacy, as is the case of fluoroqui...

Full description

Saved in:
Bibliographic Details
Main Authors: L. Angel Veyna-Hurtado, Hiram Hernández-López, Fuensanta del Rocío Reyes-Escobedo, Denisse de Loera, Salvador García-Cruz, Lorena Troncoso-Vázquez, Marisol Galván-Valencia, Julio E. Castañeda-Delgado, Alberto Rafael Cervantes-Villagrana
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Current Issues in Molecular Biology
Subjects:
Online Access:https://www.mdpi.com/1467-3045/47/2/110
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the last decades, most bacterial strains have become increasingly resistant to antibiotics. This led the WHO to declare a global emergency in 2017 and urge the development of new active compounds. Some families of antibiotics still show high antibacterial efficacy, as is the case of fluoroquinolones, which have a broad spectrum of action. For this reason, our research group derived several compounds from fluoroquinolones, selecting a compound with good antibacterial activity for further evaluations, a difluoroboranil-fluoroquinolone complex labeled <b>7a</b>. Antibacterial activity was evaluated using the Kirby–Bauer method against <i>S. aureus</i> (clinical isolate HGZ2201#ID). The MIC and MBC were obtained by macrodilutions and reseeding. In vivo antimicrobial activity was evaluated in a Balb/c mouse model infected intratracheally with <i>S. aureus</i> and subsequently treated with ciprofloxacin or <b>7a</b> (80 mg/kg/day) for five days. A mean of 8.55 ± 0.395 cm<sup>2</sup> inhibition area was observed using <b>7a</b>, while ciprofloxacin generated a mean inhibition of 7.86 ± 0.231 cm<sup>2</sup>. Compound <b>7a</b> showed a MIC and MBC of 0.25 μg/mL. This reduced the generation of pneumonic lung tissue to 5.83%, while the untreated infected group generated 60.51% of pneumonic tissue. Compound <b>7a</b> proved to be an antimicrobial agent capable of inhibiting the in vitro development of <i>S. aureus</i>. Furthermore, <b>7a</b> showed effectiveness in decreasing the progression of acute pneumonia induced by <i>S. aureus</i> in a murine model.
ISSN:1467-3037
1467-3045